CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety Article / By Mike Echalaz CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety Leia mais »
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer Article / By Mike Echalaz Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer Leia mais »
Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib Article / By Mike Echalaz Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib Leia mais »
Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer Article / By Mike Echalaz Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer Leia mais »
Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial Article / By Mike Echalaz Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial Leia mais »
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial Article / By Mike Echalaz Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial Leia mais »
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Article / By Mike Echalaz Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Leia mais »
CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective Article / By Mike Echalaz CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective Leia mais »
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial Article / By Mike Echalaz Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial Leia mais »
Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review Article / By Mike Echalaz Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review Leia mais »
